Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383 | 0.94 | CES1 (0.80) | CES1SRCKCNN4LMNATSHR | |
| Bicarbonate SCHEMBL1969231 | 0.92 | CES1 (0.77) | CES1SRCKCNN4LMNATSHR | |
| Acetic Acid SCHEMBL8064559 | 0.91 | CES1 (0.75) | CES1SRCKCNN4LMNATSHR | |
| Carbamic Acid SCHEMBL17186652 | 0.89 | CES1 (0.73) | CES1SRCKCNN4POLBLMNA | |
| SCHEMBL869019 | 0.87 | CES1 (0.73) | CES1SRCKCNN4LMNATSHR | |
| Acrylic Acid SCHEMBL10353170 | 0.85 | CES1 (0.67) | CES1SRCKCNN4TSHRTDP1 | |
| SCHEMBL1679763 | 0.84 | CES1 (1.00) | CES1SRCKCNN4POLBLMNA | |
| SCHEMBL15173 | 0.84 | CES1 (1.00) | CES1SRCKCNN4POLBLMNA | |
| Methoxymethane SCHEMBL28719477 | 0.82 | CES1 (0.96) | CES1SRCKCNN4POLBLMNA | |
| Formaldehyde SCHEMBL1128921 | 0.80 | CES1 (0.93) | CES1SRCKCNN4POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983288-B1 | SYNTHESIS OF OLIGONUCLEOTIDES | QUIATECH AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| US-6790946-B2 | GENERATING IMMBOLIZED NUCLEOTIDE SEQUENCES; OBTAIN NUCLEOTIDE SEQUENCES, ATTACH TO SOLID SUPPORT, RELEASE TERMINAL OF OLIGONUCLEOTIDE | QUIATECH AB (SE) | 2004-09-14 | — | — | US | disclosed |
| EP-0815114-B1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | UNIV DUKE (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1021452-B1 | PROCESS FOR SYNTHESIZING PHOSPHODIESTERS | EPIX MEDICAL INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020051994-A1 | Synthesis of oligonucleotides | KWIATKOWSKI MAREK (SE) | 2002-05-02 | — | — | US | disclosed |
| US-6313284-B1 | Solid phase synthesis | MAREK KWIATKOWSKI (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1021452-A1 | PROCESS FOR SYNTHESIZING PHOSPHODIESTERS | Epix Medical, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0983288-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | Kwiatkowski, Marek (SE) | 2000-03-08 | — | — | EP | disclosed |
| US-5919967-A | Process for synthesizing phosphodiesters | EPIX MEDICAL, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| US-5908926-A | 5'to 3' nucleic acid synthesis using 3'-photoremovable protecting group | DUKE UNIVERSITY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0815114-A4 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | UNIV DUKE (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998051698-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | KWIATKOWSKI MAREK (SE) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998046612-A1 | PROCESS FOR SYNTHESIZING PHOSPHODIESTERS | EPIX MEDICAL, INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0815114-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028457-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051994-A1 | Synthesis of oligonucleotides | RNGTT, POLR2H, POLR2E | CES1 3410/4885SRC 1705/4885PTPN1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.